142 related articles for article (PubMed ID: 8595160)
1. Cancer cell progression and chemoimmunotherapy--dual effects in the induction of resistance to therapy.
Hamuro J; Kikuchi T; Takatsuki F; Suzuki M
Br J Cancer; 1996 Feb; 73(4):465-71. PubMed ID: 8595160
[TBL] [Abstract][Full Text] [Related]
2. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.
Suzuki M; Kikuchi T; Takatsuki F; Hamuro J
Cancer Immunol Immunother; 1994 Jan; 38(1):1-8. PubMed ID: 8299113
[TBL] [Abstract][Full Text] [Related]
3. Lentinan augments skin reaction induced by bradykinin: its correlation with vascular dilatation and hemorrhage responses and antitumor activities.
Takatsuki F; Namiki R; Kikuchi T; Suzuki M; Hamuro J
Int J Immunopharmacol; 1995 Jun; 17(6):465-74. PubMed ID: 7499022
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antimetastatic effects of lentinan and interleukin 2 with pre- and post-operative treatments.
Hamuro J; Takatsuki F; Suga T; Kikuchi T; Suzuki M
Jpn J Cancer Res; 1994 Dec; 85(12):1288-97. PubMed ID: 7852191
[TBL] [Abstract][Full Text] [Related]
5. Complete regression of Lewis lung carcinoma by cyclophosphamide in combination with immunomodulators.
Abe S; Takahashi K; Yamazaki M; Mizuno D
Jpn J Cancer Res; 1985 Jul; 76(7):626-30. PubMed ID: 3928559
[TBL] [Abstract][Full Text] [Related]
6. Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.
Wu Y; Deng Z; Wang H; Ma W; Zhou C; Zhang S
BMC Immunol; 2016 Sep; 17(1):29. PubMed ID: 27645787
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta 1 (TGF-beta 1) produced in tumour tissue after chemotherapy acts as a lymphokine-activated killer attractant.
Kuramitsu Y; Nishibe M; Kobayashi M; Togashi Y; Yuan L; Takizawa M; Okada F; Hosokawa M
Br J Cancer; 1996 Jul; 74(2):274-9. PubMed ID: 8688335
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.
Li XF; Takiuchi H; Zou JP; Katagiri T; Yamamoto N; Nagata T; Ono S; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1993 Mar; 84(3):315-25. PubMed ID: 8098027
[TBL] [Abstract][Full Text] [Related]
9. [Effects of pretreatment with lentinan or krestin on antitumor effector cell activities suppressed by cyclophosphamide].
Yang ZB
Hokkaido Igaku Zasshi; 1994 Jan; 69(1):137-45. PubMed ID: 8119654
[TBL] [Abstract][Full Text] [Related]
10. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response.
Rossowska J; Anger N; Kicielińska J; Pajtasz-Piasecka E; Bielawska-Pohl A; Wojas-Turek J; Duś D
Immunobiology; 2015 Mar; 220(3):389-98. PubMed ID: 25454807
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis.
Suga T; Shiio T; Maeda YY; Chihara G
Cancer Res; 1984 Nov; 44(11):5132-7. PubMed ID: 6488173
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
[TBL] [Abstract][Full Text] [Related]
13. Improvement of erythroid toxicity by lentinan and erythropoietin in mice treated with chemotherapeutic agents.
Takatsuki F; Miyasaka Y; Kikuchi T; Suzuki M; Hamuro J
Exp Hematol; 1996 Feb; 24(3):416-22. PubMed ID: 8599970
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
[TBL] [Abstract][Full Text] [Related]
15. Failure to relate the anti-tumour action of cyclophosphamide with the immunogenicity of two murine fibrosarcomas.
Evans R
Int J Cancer; 1978 May; 21(5):611-6. PubMed ID: 659026
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of Madison 109 lung carcinoma and other murine tumors using lentinan.
Rose WC; Reed FC; Siminoff P; Bradner WT
Cancer Res; 1984 Apr; 44(4):1368-73. PubMed ID: 6704958
[TBL] [Abstract][Full Text] [Related]
17. Active immunotherapy with Corynebacterium parvum and chemotherapy in murine fibrosarcomas.
Currie GA
Br Med J; 1970 Feb; 1(5695):541-4. PubMed ID: 5435189
[TBL] [Abstract][Full Text] [Related]
18. Active specific chemoimmunotherapy of lymph-node metastasis from a poorly immunogenic murine fibrosarcoma.
Naito K; Oka T; Nomi S; Yamagishi H; Kahan BD
Jpn J Cancer Res; 1989 Nov; 80(11):1119-26. PubMed ID: 2514172
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model.
Eggermont AM; Sugarbaker PH
Br J Cancer; 1988 Oct; 58(4):410-4. PubMed ID: 3264714
[TBL] [Abstract][Full Text] [Related]
20. [Granulopoietic effects of lentinan in mice: effects on GM-CFC and 5-FU-induced leukopenia].
Matsuo T; Kurahashi Y; Nishida S; Kumada K; Hayami T; Takagi T
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1310-4. PubMed ID: 3579329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
